Big Pharma
21 November 2025 The week exposed fractures in the UK's industry—but also unexpected reasons for optimism. Five themes dominated conversations about the direction of the country's life sciences sector.
20 November 2025
20 November 2025
19 November 2025
18 November 2025
14 November 2025
Latest Features
Americas
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko.
More News
13 November 2025 Inconsistent Bolar interpretations and tougher trial disclosures are tightening the squeeze on innovators in life sciences, counsel told LSPN Europe. Tom Phillips reports.
13 November 2025 Pharma company tells court generics rival’s petition is “not the subject of any legal conflict”, as it reassures investors that a $12bn biotech acquisition will deliver growth.
13 November 2025 US Federal Trade Commission’s antitrust warning tipped the scales in Pfizer’s favour, ending a heated dispute over a weight-loss biotech.
13 November 2025 Regeneron’s Adam Gastonguay shares how to raise the profile of your IP team, get the most from outside counsel, and stay ahead of the growing pressure to adopt AI.
10 November 2025 According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.
6 November 2025 Judge delivers major setback to pharma giant’s efforts to scupper rival’s surprise bid, in an increasingly bitter feud over an obesity drug biotech.
6 November 2025 Womble Bond Dickinson has expanded its West Coast footprint with the addition of a seasoned patent litigator, strengthening the firm’s life sciences capabilities amid rising IP disputes and rapid biotech innovation.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox